Asia Pacific Blood Glucose Monitoring Devices Market

The Asia Pacific blood glucose monitoring devices market is projected to reach USD 5.86 billion in 2030 from USD 3.45 billion in 2025, at a CAGR of 11.2% during the forecast period. The Asia Pacific blood glucose monitoring devices market is experiencing growth due to an increase in diabetes cases, complemented by governments' growing attention towards early diagnosis, managing the disease effectively, and reducing complications resulting from diabetes in both developed and developing economies. The rise in the availability of healthcare services, the improvement of reimbursement coverage in some markets, and the increasing availability of outpatient and home-based care facilities are factors that are helping the spread of the use of self-monitoring blood glucose (SMBG) devices and, to an extent, continuous glucose monitoring (CGM) systems. Doctors' preference for accurate, clinically validated monitoring solutions, especially for insulin-dependent and high-risk patients, also supports market demand. Moreover, public health measures at the country level to enhance glycemic control, along with increased patient knowledge and smartphone-enabled digital health integration, are contributing to the growth in use, particularly in Japan, Australia, South Korea, and major cities in China and India. Nonetheless, the expansion of the market is limited by the presence of a significant price sensitivity, the lack of reimbursement for CGM in many countries, and the dependence on tender-based procurement and low-cost domestic manufacturers, which could hinder the widespread usage of advanced and premium glucose monitoring technologies in several Asia Pacific markets.

Prominent players in the Asia Pacific blood glucose monitoring devices market include Abbott Laboratories (US), Medtronic (Ireland), Sinocare (China), F. Hoffmann-La Roche Ltd. (Switzerland), DexCom, Inc. (US), i-SENS, Inc. (South Korea), and Ascensia Diabetes Care Holdings AG (Switzerland).

To know about the assumptions considered for the study download the pdf brochure

• In May 2023, Roche announced that their blood glucose monitoring device 'Accu-Chek Active' is now manufactured in India.
• In February 2023, DexCom, Inc. (US) announced the launch of the Dexcom G6 Continuous Glucose Monitoring System in Singapore.

Abbott Laboratories (US) is a global healthcare leader operating in over 160 countries. Through its Medical Devices division, the company has built a strong presence in diabetes care, offering both continuous and traditional blood glucose monitoring solutions under the FreeStyle brand. Its flagship FreeStyle Libre system, comprising sensors, test strips, data management software, and related accessories, has revolutionized glucose tracking by providing real-time insights for better diabetes management. Additionally, the launch of the Lingo continuous glucose monitoring system for broader health and wellness applications has further strengthened Abbott’s position as an innovation leader in the blood glucose monitoring devices market.

DexCom, Inc. (US) develops, manufactures, and commercializes real-time CGM systems that provide continuous, actionable insights into glucose levels without the need for routine fingersticks. Its flagship DexCom G6 and next-generation G7 systems, supported by integrated mobile applications and data platforms, enable improved glycemic control and patient engagement. With a strong global presence across North America, Europe, and expanding markets in the Asia Pacific, DexCom has established itself as a key innovator and market leader in CGM solutions, driving advancements in digital health and diabetes care.

Medtronic (Ireland) has a diversified portfolio encompassing cardiovascular, neuroscience, surgical, and diabetes care solutions. In the field of diabetes management, the company develops and markets advanced insulin delivery systems integrated with continuous glucose monitoring (CGM) technologies. Its flagship MiniMed insulin pump series, paired with Guardian CGM sensors and intelligent insulin management software, enables real-time glucose tracking and automated insulin delivery to help patients achieve better glycemic control. With a strong footprint across North America, Europe, and emerging markets, Medtronic continues to drive innovation in diabetes care, advancing toward fully closed-loop systems and strengthening its position as a leader in the blood glucose monitoring devices market.

MARKET RANKING

The Asia Pacific blood glucose monitoring devices market is characterized by the presence of a mix of established global leaders and strong regional manufacturers, operating across highly diverse healthcare systems with varying levels of reimbursement, pricing controls, and technology adoption. Abbott Laboratories leads the regional market, supported by the expanding penetration of its FreeStyle Libre CGM systems, particularly in developed markets such as Japan, Australia, and South Korea, as well as growing uptake in urban centers across China and Southeast Asia, driven by ease of use and rising patient awareness. Dexcom holds a prominent position in the CGM segment, with increasing adoption of its G6 and G7 platforms in specialist diabetes centers and digitally enabled care settings, although reimbursement remains uneven across the region. Medtronic maintains a solid presence through its MiniMed insulin pump systems and Guardian CGM sensors, with demand largely concentrated in advanced healthcare markets focusing on integrated and closed-loop diabetes management solutions. Roche continues to retain a stable share in Asia Pacific through its Accu-Chek SMBG portfolio, benefiting from long-standing physician trust, broad distributor networks, and strong presence in hospital and retail pharmacy channels. In parallel, Sinocare has emerged as a key regional player, particularly in China and neighboring markets, leveraging cost-competitive SMBG devices and strong domestic distribution to capture volume-driven demand, while i-SENS is gaining traction across the Asia Pacific with its CareSens product portfolio, supported by competitive pricing, manufacturing scale, and gradual expansion into continuous glucose monitoring, positioning it as a notable challenger within the region.

Related Reports:

Asia Pacific Blood Glucose Monitoring Devices Market by Product Type (Self-blood glucose monitoring, Professional point of care), Application (Diabetes management, Health & wellness Monitoring), Test Site (Fingertip, Upper arm), End User (Self/Homecare) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com